Amylin analogues and pharmaceutical compositions thereof

1. A polypeptide comprising an amino acid sequence which is an analogue of SEQ ID No: 2 wherein:

said analogue comprises a proline residue at position 37, a glutamic acid at position 14 and an arginine at position 17;

wherein the amino acid sequence numbering of the analogue corresponds to the amino acid numbering sequence of SEQ ID No: 2.

2. The polypeptide of claim 1 wherein at least one substituent is attached to at least one amino acid residue of said polypeptide.

3. The polypeptide of claim 2 wherein the substituent is selected from the group consisting of C20diacid, C20diacid-γGlu, C20diacid-γGlu-γGlu, C20diacid-γGlu-γGlu-γGlu, C20diacid-OEG, C20diacid-γGlu-OEG, C20diacid-γGlu-OEG-OEG, C18diacid-γGlu, C16diacid-γGlu, and C14diacid-γGlu.

4. The polypeptide of claim 2 wherein the substituent is attached to the α-amino group of the N-terminal amino acid residue or to a Lys residue.

5. The polypeptide of claim 1 wherein the polypeptide is:

N-alpha-[(S)-4-Carboxy-4-(19-carboxynonadecanoylamino)butyryl]-[Glu14,Arg17,Pro37]-pramlintide.

6. A method of treating type 2 diabetes or obesity, comprising administering the polypeptide of claim 1 .

7. A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable excipient.

8. A process for preparing a pharmaceutical composition comprising mixing the polypeptide of claim 1 with at least one pharmaceutically acceptable excipient.

9. A method of treating type 2 diabetes or obesity, comprising administering the polypeptide of claim 5 .

10. A pharmaceutical composition comprising the polypeptide of claim 5 and a pharmaceutically acceptable excipient.

11. A process for preparing a pharmaceutical composition comprising mixing the polypeptide of claim 5 with at least one pharmaceutically acceptable excipient.